WDNA vs. XBI

Last updated Jun 24, 2026

WDNA (WisdomTree BioRevolution Fund) and XBI (SPDR S&P Biotech ETF) are both Health & Biotech Equities funds - WDNA tracks the WisdomTree BioRevolution Index while XBI tracks the S&P Biotechnology Select Industry Index. Both are passively managed. Over the past 5 years, WDNA returned -5.03%/yr vs 1.51%/yr for XBI. Their correlation of 0.90 suggests significant overlap in exposure. WDNA charges 0.45%/yr vs 0.35%/yr for XBI.

Performance

WDNA vs. XBI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Biotech ETF (XBI). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, WDNA achieves a 13.32% return, which is significantly lower than XBI's 20.70% return.

WDNA

• 1D: 0.49%
• 1M: 8.93%
• YTD: 13.32%
• 6M: 11.11%
• 1Y: 50.90%
• 3Y*: 5.47%
• 5Y*: -5.03%
• 10Y*: —

XBI

• 1D: 0.80%
• 1M: 11.78%
• YTD: 20.70%
• 6M: 17.84%
• 1Y: 79.53%
• 3Y*: 20.24%
• 5Y*: 1.51%
• 10Y*: 11.14%

*Multi-year figures are annualized to reflect compound growth (CAGR)

WDNA vs. XBI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
WDNA WisdomTree BioRevolution Fund	13.32%	22.68%	-14.18%	-2.07%	-26.29%	-4.92%
XBI SPDR S&P Biotech ETF	20.70%	35.89%	1.01%	7.60%	-25.87%	-12.01%

Correlation

The correlation between WDNA and XBI is 0.86, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.86
Correlation (3Y) Calculated over the trailing 3-year period	0.89
Correlation (5Y) Calculated over the trailing 5-year period	0.90
Correlation (All Time) Calculated using the full available price history since Jun 3, 2021	0.90

The correlation between WDNA and XBI has been stable across timeframes, ranging from 0.86 to 0.90 - a consistent structural relationship.

WDNA vs. XBI - Sectors Allocation Comparison

Sectors	WDNA	XBI
Healthcare	85.0%	99.7%
Basic Materials	6.5%	0.2%
Consumer Defensive	3.0%	-
Energy	1.1%	-
Communication Services	-	-
Consumer Cyclical	-	-
Financial Services	-	0.3%
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

WDNA vs. XBI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

WDNA

WDNA Risk / Return Rank: 66
WDNA Sharpe Ratio Rank: 65
WDNA Sortino Ratio Rank: 66
WDNA Omega Ratio Rank: 56
WDNA Calmar Ratio Rank: 85
WDNA Martin Ratio Rank: 59

XBI

XBI Risk / Return Rank: 90
XBI Sharpe Ratio Rank: 91
XBI Sortino Ratio Rank: 89
XBI Omega Ratio Rank: 82
XBI Calmar Ratio Rank: 96
XBI Martin Ratio Rank: 94

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

WDNA vs. XBI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	WDNA	XBI	Difference
Sharpe ratio: Return per unit of total volatility	1.98	3.02	-1.04
Sortino ratio: Return per unit of downside risk	2.81	3.89	-1.08
Omega ratio: Gain probability vs. loss probability	1.32	1.47	-0.14
Calmar ratio: Return relative to maximum drawdown	4.37	8.22	-3.85
Martin ratio: Return relative to average drawdown	9.80	24.30	-14.50

WDNA vs. XBI - Sharpe Ratio Comparison

The current WDNA Sharpe Ratio is 1.98, which is lower than the XBI Sharpe Ratio of 3.02. The chart below compares the historical Sharpe Ratios of WDNA and XBI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

WDNA vs. XBI - Drawdown Comparison

The maximum WDNA drawdown since its inception was -58.87%, smaller than the maximum XBI drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for WDNA and XBI.

Drawdown Indicators

	WDNA	XBI	Difference
Max Drawdown Largest peak-to-trough decline	-58.87%	-63.89%	+5.02%
Max Drawdown (1Y) Largest decline over 1 year	-11.70%	-9.72%	-1.98%
Max Drawdown (3Y) Largest decline over 3 years	-38.25%	-32.99%	-5.26%
Max Drawdown (5Y) Largest decline over 5 years	-58.87%	-54.71%	-4.16%
Max Drawdown (10Y) Largest decline over 10 years	—	-63.89%	—
Current Drawdown Current decline from peak	-27.05%	-14.94%	-12.11%
Average Drawdown Average peak-to-trough decline	-35.56%	-20.93%	-14.63%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.21%	3.28%	+1.93%

Volatility

WDNA vs. XBI - Volatility Comparison

The current volatility for WisdomTree BioRevolution Fund (WDNA) is 7.39%, while SPDR S&P Biotech ETF (XBI) has a volatility of 9.96%. This indicates that WDNA experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	WDNA	XBI	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.39%	9.96%	-2.57%
Volatility (6M) Calculated over the trailing 6-month period	16.98%	21.31%	-4.33%
Volatility (1Y) Calculated over the trailing 1-year period	25.90%	26.47%	-0.57%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.14%	32.30%	-7.16%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.06%	32.01%	-6.95%

WDNA vs. XBI - Expense Ratio Comparison

WDNA has a 0.45% expense ratio, which is higher than XBI's 0.35% expense ratio.

Dividends

WDNA vs. XBI - Dividend Comparison

WDNA's dividend yield for the trailing twelve months is around 4.03%, more than XBI's 0.39% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
WDNA WisdomTree BioRevolution Fund	4.03%	4.57%	0.75%	0.80%	0.38%	0.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
XBI SPDR S&P Biotech ETF	0.39%	0.37%	0.15%	0.02%	0.00%	0.04%	0.20%	0.00%	0.28%	0.24%	0.26%	0.61%

Frequently Asked Questions

Can I hold both WDNA and XBI in my portfolio?

WDNA and XBI have a correlation of 0.86, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, WDNA or XBI?

XBI has higher volatility (9.96%) compared to WDNA (7.39%). In terms of maximum drawdown, WDNA dropped -58.87% vs XBI's -63.89%.

Which ETF is better, WDNA or XBI?

On 5-year performance, XBI leads with 1.51% vs -5.03% for WDNA. On fees, XBI is cheaper at 0.35% per year. On volatility, WDNA has been the lower-risk option at 7.39%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, WDNA or XBI?

Over the 5-year period, XBI has performed better with a 1.51% return vs -5.03%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, WDNA or XBI?

XBI is cheaper with a 0.35% expense ratio, compared with 0.45% for WDNA.

Which ETF pays a higher dividend yield, WDNA or XBI?

WDNA has the higher dividend yield at 4.03%, compared with 0.39% for XBI.

What is the main difference between WDNA and XBI?

WDNA tracks WisdomTree BioRevolution Index, while XBI tracks S&P Biotechnology Select Industry Index. They also come from different issuers: WisdomTree and State Street. Their fees differ too: 0.45% for WDNA and 0.35% for XBI.

Which has better risk-adjusted returns?

XBI currently has the higher Sharpe Ratio (3.02 vs 1.98), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.